{"id":4211,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2014-05-02","marketCap":282.25238037109375,"name":"Aldeyra Therapeutics Inc","phone":"17817614904","outstanding":59.40999984741211,"symbol":"ALDX","website":"https://www.aldeyra.com/","industry":"Biotechnology"},"price":4.87105,"year":2024,"month":8,"day":13,"weekday":"Tuesday","title":"Historical Performance of Aldeyra Therapeutics Inc Stock Compared to Industry Benchmarks","date":"2024-08-13","url":"/posts/2024/08/13/ALDX","content":[{"section":"Introduction","text":"Aldeyra Therapeutics Inc is a biotechnology company that focuses on the development and commercialization of therapeutic products for immune-mediated diseases. To evaluate the historical performance of Aldeyra Therapeutics Inc stock, we will compare its price movements and returns to industry benchmarks."},{"section":"Stock Performance","text":"To analyze the stock performance, we can examine the historical price movements of Aldeyra Therapeutics Inc stock. By comparing its price trends to industry benchmarks, we can assess whether the stock has outperformed or underperformed the broader industry."},{"section":"Returns","text":"In addition to price movements, it is crucial to analyze the returns generated by Aldeyra Therapeutics Inc stock. This includes calculating the cumulative return over a specific period and comparing it to industry benchmarks. Returns provide insights into the overall profitability of an investment in the stock."},{"section":"Volatility","text":"Volatility is another important factor to consider when evaluating stock performance. By measuring the volatility of Aldeyra Therapeutics Inc stock using metrics like standard deviation or beta, we can assess its stability and compare it to the industry average. Lower volatility indicates a more stable stock."},{"section":"Fundamental Analysis","text":"Analyzing fundamental factors such as earnings per share (EPS), revenue growth, and profitability ratios can offer insights into the financial health of Aldeyra Therapeutics Inc. By comparing these metrics to industry benchmarks, we can determine if the company is performing better or worse than its peers."},{"section":"Market Share","text":"Examining Aldeyra Therapeutics Inc's market share within the industry can also provide context for the stock's historical performance. If the company has gained or lost market share over time, it can impact its stock performance."},{"section":"Industry Benchmarks","text":"To gauge the performance of Aldeyra Therapeutics Inc stock accurately, it is essential to choose appropriate industry benchmarks. These benchmarks can include sector-specific indices or peer companies within the biotechnology sector. Comparing Aldeyra Therapeutics Inc stock to these benchmarks allows for a more accurate assessment of its historical performance."},{"section":"Conclusion","text":"Through analyzing the historical performance of Aldeyra Therapeutics Inc stock in comparison to industry benchmarks, we can objectively evaluate its performance. Factors such as stock price movements, returns, volatility, fundamental analysis, market share, and appropriate industry benchmarks provide meaningful insights into the stock's historical performance."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1723206360,"headline":"Buy Recommendation for Aldeyra Therapeutics Amid Positive Phase 3 Results for Reproxalap","id":129272643,"image":"","symbol":"ALDX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593615895"},{"category":"company","date":1723199571,"headline":"Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint","id":129261269,"image":"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/pt-shutterstock_504256120.jpg","symbol":"ALDX","publisher":"Yahoo","summary":"The investigational new drug candidate Reproxalap is intended for the treatment of dry eye disease and allergic conjunctivitis.","url":"https://www.clinicaltrialsarena.com/news/aldeyras-iii-reproxalap-primary/"},{"category":"company","date":1723186380,"headline":"Aldeyra Therapeutics: A Buy Rating on Strong Clinical Progress and Market Potential","id":129272644,"image":"","symbol":"ALDX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593868604"},{"category":"company","date":1723116720,"headline":"Aldeyra climbs after late-stage success for dry eye disease therapy","id":129234431,"image":"","symbol":"ALDX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592230334"},{"category":"company","date":1723114800,"headline":"Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap","id":129232715,"image":"https://media.zenfs.com/en/business-wire.com/23ce0625ae68d499fe8389a1f0119b53","symbol":"ALDX","publisher":"Yahoo","summary":"LEXINGTON, Mass., August 08, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxa","url":"https://finance.yahoo.com/news/aldeyra-therapeutics-achieves-primary-endpoint-110000999.html"},{"category":"company","date":1723099980,"headline":"Aldeyra Therapeutics Announces Major Dry Eye Treatment Success","id":129234433,"image":"","symbol":"ALDX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3591799309"},{"category":"company","date":1723060860,"headline":"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap","id":129229133,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"ALDX","publisher":"Yahoo","summary":"LEXINGTON, Mass., August 07, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the Phase 3 dry eye disease clinical trial of reproxalap.","url":"https://finance.yahoo.com/news/aldeyra-therapeutics-schedules-conference-call-200100368.html"},{"category":"company","date":1723033740,"headline":"Buy Rating on Aldeyra Therapeutics Backed by Strong Drug Pipeline and Lead Candidate’s Market Potential","id":129226303,"image":"","symbol":"ALDX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3589580718"},{"category":"company","date":1722576420,"headline":"Buy Rating Affirmed for Aldeyra Therapeutics Amid Promising Drug Trials and Broad RASP Platform Prospects","id":129109694,"image":"","symbol":"ALDX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3583027596"},{"category":"company","date":1722430894,"headline":"Owning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),","id":129044248,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"ALDX","publisher":"Yahoo","summary":"Key Insights Significantly high institutional ownership implies Aldeyra Therapeutics' stock price is sensitive to their...","url":"https://finance.yahoo.com/news/owning-36-shares-institutional-owners-130134280.html"}]}